Shamburg News · 8-K filed Nov 13, 2026, 4:59 PM EST
Evofem Biosciences Reports Third Quarter 2026 Results With $0.9 Million Net Income
EVFM · Evofem Biosciences, Inc.
- Earnings
- Financial statements
- Materiality: high
Evofem Biosciences reported third quarter 2026 product sales, net, of $4.6 million, down from $5.0 million in the prior year period. Income from operations was $0.7 million, compared with $1.0 million in Q3 2025. Net income attributable to common stockholders was $0.9 million, or $0.01 per basic share, versus a net loss of $1.7 million in the prior year quarter.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001493152-26-051806.
Written from the filing by Shamburg Markets. Figures are as reported by the company.